• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Cervical Cancer

Tackle Cervical Cancer from every angle with our wide range of antibodies and IHC kits

Typically caused by HPV infection, cervical cancer is one of the most common forms of cancer amongst women, with roughly 13,000 new cases in the US each year. Through proper screening and detection methods during the early stages of disease progression, cervical cancer can be easily managed and treated. This involves identifying elevated levels of biomarkers that are associated with HPV infection, cell cycle progression, epithelial differentiation, and cell metastasis. Proteintech offers antibodies against over 20 prominent cervical cancer biomarkers, plus many more in our portfolio of over 13,000 antibodies.  

 

Featured Markers for Cervical Cancer Detection
P16INK4a

p16INK4a is an important cell cycle regulator that typically inhibits cyclin-dependent kinase (CDK) 4/6 activity. While its levels in the cervical epithelial cells are normally low, HPV infection results in the expression of oncoproteins that promote cell cycle progression, which in turn triggers in increase in p16 production. As such p16INK4a can be used as a highly specific marker to detect HPV-triggered, cervical cancer oncogenesis. Proteintech’s pI6INK4a polyclonal antibody has been cited over 250 times – more than any other polyclonal p16INK4a antibody on the market. 

IHC analysis of paraffin-embedded human cervical cancer using p16INK4a antibody

Immunohistochemical analysis of paraffin-embedded human cervical cancer using 10883-1-AP (p16INK4a antibody) at dilution of 1:2000 (under 10x lens). 

 

Cytokeratin 7 (CK7)

The cytokeratin profile of cells can often change in response to internal transformation and metastatic events. Cytokeratin 7 (CK7) is typically a marker for cervical squamous cell junctions. These cells are thought to be a site of entry of HPV infection and vulnerable to transformation. Therefore, high CK7 expression is often used as a marker to indicate cervical cancer progression.

IHC analysis of paraffin-embedded human cervical cancer KRT7 Specific antibody

Immunohistochemical analysis of paraffin-embedded human cervical cancer using 171513-1-AP (KRT7 Specific antibody) at dilution of 1:50 (under 10x lens)

 

MMP9

Matrix metalloproteinases (MMPs) are involved in the breakdown of the extracellular matrix, which is a crucial step in both normal physiological processes such as embryonic development as well as disease processes such as metastases. HPV oncoproteins can upregulate the expression of these proteins resulting in increased metastasis to additional sites. MMP9 has been associated with increased invasiveness of cervical cancer and has potential to be used as prognostic marker for disease progression. Proteintech’s MMP9 antibody has been cited over 870 times, more than most other MMP9 antibodies on the market.

IHC analysis of paraffin-embedded human cervical cancer tissue slide using MMP9 (N-terminal) antibody

Immunohistochemical analysis of paraffin-embedded human cervical cancer tissue slide using 10375-2-AP (MMP9, N-terminal antibody) at dilution of 1:200 (under 10x lens).

 

Antibodies for Cervical Cancer Research
Function Marker PTG catalog

Cell Cycle and Proliferation

p16INK4a

10883-1-AP

Ki-67

27309-1-AP

Cyclin D1

60186-1-Ig

pRb

10048-2-Ig

MCM2

10513-1-AP

p53

10442-1-AP

p63

12143-1-AP

TOP2A

20233-1-AP

OVCA1

20112-1-AP

Apoptosis

BCL-2

12789-1-AP

BAX

50599-2-Ig

Epithelial Differentiation

CK8

17514-1-AP

CK17

17516-1-AP

CK19

10712-1-AP

CK7

17513-1-AP

Cell Adhesion, Invasion, and Metastasis

MT1-MMP/MMP-14

14552-1-AP

MMP-1

10371-2-AP

MMP-9

10375-2-AP

Cell Stemness

Nanog

14295-1-AP

ALDH1

15910-1-AP

OCT4

11263-1-AP

Angiogenesis

VEGF

19003-1-AP
IHC Kits for Cervical Cancer Research
Function Marker PTG catalog

Cell Cycle and Proliferation

p53

KHC0079

p63

KHC0086

Apoptosis

BCL-2

KHC0012

BAX

KHC0768

Epithelial Differentiation

CK8

KHC0041

CK17

KHC0753

CK19

KHC0033

CK7

KHC0204/KHC0748

Cell Adhesion, Invasion, and Metastasis

MMP-1

KHC0804

MMP-9

KHC0120

Cell Stemness

ALDH1

KHC0084

Angiogenesis

VEGF

KHC0735



 

References

Alva N, N., A, S., Shetty, P., & Mysorker, V. (2022). A Study of Cytokeratin-7 Expression and Clinicopathological Correlation in Dysplasia and Squamous Cell Carcinoma of the Cervix. Asian Pacific Journal of Cancer Prevention, 23(3), 885–891. https://doi.org/10.31557/apjcp.2022.23.3.885

Roden, R., & Wu, T. C. (2006). How will HPV vaccines affect cervical cancer? Nature Reviews Cancer, 6(10), 753–763. https://doi.org/10.1038/nrc1973

Kaewprag, J., Umnajvijit, W., Ngamkham, J., & Ponglikitmongkol, M. (2013). HPV16 Oncoproteins Promote Cervical Cancer Invasiveness by Upregulating Specific Matrix Metalloproteinases. PLoS ONE, 8(8), e71611. https://doi.org/10.1371/journal.pone.0071611

Volkova, L. V., Pashov, A. I., & Omelchuk, N. N. (2021). Cervical Carcinoma: Oncobiology and Biomarkers. International Journal of Molecular Sciences, 22(22), 12571. https://doi.org/10.3390/ijms222212571